Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors
Recruitment Status: Recruiting
Start Date: June 09, 2021
End Date: June 01, 2027
Inclusion Criteria:
- Malignancy which the treating oncologist plans for next treatment to inhibit PD-1or PD-L1 with the immune inhibitor being the only immunotherapy. Twenty-five subjects in a separate cohort will need for eligibility to be planned for treatment with anti-PD1/PD-L1 plus antri-CTLA-4 therapy.
- Willingness to complete symptom questionnaires
- Willingness to allow blood draws
- Ability to provide informed consent
- Age > 18 years old
Exclusion Criteria:
- History of clinical or subclinical hyperthyroidism or hypothyroidism
- Hemoglobin < 9
- Inability to come for all study visits.
- Actively on vitamin D supplementation due to vitamin D deficiency (As part of a multivitamin is not exclusionary)
- Pregnant or lactating
- History of hypophysitis
-
Conditions:
- Thyroid Diseases
- Neoplasms
- Vitamin D Deficiency